Compare Eli Lilly And Co (LLY) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

QDTY trades at $39.53 with minimal daily movement (+0.15%). The stock demonstrates consistent dividend distributions with weekly payouts ranging from $0.22 to $0.32 per share throughout 2026. Technical indicators show stable price action while fundamental metrics remain undisclosed in available data. Recent corporate actions focus exclusively on dividend distributions with no significant business developments reported.

The outlook for QDTY appears income-focused given the regular dividend schedule, though fundamental analysis is limited by missing financial ratios. Key risks include dependency on dividend sustainability and potential market volatility. Investment appeal centers on yield generation rather than growth prospects, requiring careful monitoring of underlying financial health.